FGF21 and metabolic disease: Currently, the development of FGF21 analogues or mimics through biopharmaceutical engineering approaches also greatly enriches the possibility of FGF21 as a therapeutic target for metabolic diseases, such as the clinical trials of LY2405319 and PF-05231023 in metabolic diseases are under way.